SIAXI: Efficacy and safety of incobotulinumtoxinA for the treatment of sialorrhea in Parkinson's disease (PD) and other neurological conditions: results of a Phase III, placebo-controlled, randomised, doubleblind study

被引：0
作者：
Csikos, J. [1 ]
Blitzer, A. [2 ]
Friedman, A. [3 ]
Michel, O. [4 ,5 ]
Flatau-Baque, B. [6 ]
Jost, W.
机构：
[1] Merz Pharmaceut, Frankfurt, Germany
[2] Columbia Univ Coll Phys & Surg, Dept Otolaryngol Head & Neck Surg, 630 W 168th St, New York, NY 10032 USA
[3] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA
[4] Med Univ Warsaw, Dept Neurol, Fac Hlth Sci, Warsaw, Poland
[5] Univ Hosp Brussels, Otorhinolaryngol, Brussels, Belgium
[6] Parkinson Klin Wolfach, Wolfach, Germany
来源：
INTERNATIONAL JOURNAL OF STROKE | 2018年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [31] Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis
    Dorkin, Henry L.
    Staab, Doris
    Operschall, Elisabeth
    Alder, Jeff
    Criollo, Margarita
    BMJ OPEN RESPIRATORY RESEARCH, 2015, 2 (01): : 1 - 10
  • [32] Efficacy and safety of lanreotide in postoperative dumping syndrome: A Phase II randomised and placebo-controlled study
    Wauters, Lucas
    Arts, Joris
    Caenepeel, Philip
    Holvoet, Lieselot
    Tack, Jan
    Bisschops, Raf
    Vanuytsel, Tim
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2019, 7 (08) : 1064 - 1072
  • [33] A phase III double blind, randomised, placebo controlled study of the efficacy, safety and tolerability of idebenone in the treatment of Friedreich's ataxia patients
    Giunti, P.
    Gray, J.
    Wood, N. W.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2007, 78 (09) : 1026 - 1026
  • [34] Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
    Cummings, Jeffrey
    Isaacson, Stuart
    Mills, Roger
    Williams, Hilde
    Chi-Burris, Kathy
    Corbett, Anne
    Dhall, Rohit
    Ballard, Clive
    LANCET, 2014, 383 (9916) : 533 - 540
  • [35] Randomized, placebo-controlled study investigating the safety, pharmacokinetics and efficacy of inhaled apomorphine in Parkinson's disease patients
    Thijssen, E.
    den Heijer, J.
    Puibert, D.
    Lei, M.
    Hasegawa, D.
    Keum, K.
    Mochel, K.
    Roset, P.
    van Brummelen, E.
    Naranda, T.
    Groeneveld, G.
    MOVEMENT DISORDERS, 2020, 35 : S428 - S428
  • [36] SAFETY AND TOLERABILITY OF SELISISTAT FOR THE TREATMENT OF HUNTINGTON'S DISEASE: RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II TRIAL
    Reilmann, R.
    Squitieri, F.
    Priller, J.
    Saft, C.
    Mariotti, C.
    Suessmuth, S. D.
    Nemeth, A. H.
    Tabrizi, S. J.
    Quarrell, O.
    Craufurd, D.
    Rickards, H.
    Rosser, A.
    Darpo, B.
    Tessari, M.
    Szynol, A.
    Fischer, D. F.
    Frost, C.
    Farmer, R. E.
    Landwehrmeyer, G. B.
    Westerberg, G.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 : A102 - A102
  • [37] Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine:: results of a phase III, multicentre, placebo-controlled study across three attacks
    Stark, R
    Dahlöf, C
    Haughie, S
    Hettiarachchi, J
    CEPHALALGIA, 2002, 22 (01) : 23 - 32
  • [38] Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A phase III, randomized, double-blind, placebo-controlled study
    Mizuno, Y.
    Kondo, T.
    MOVEMENT DISORDERS, 2012, 27 : S129 - S129
  • [39] Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study
    Langerbeins, Petra
    Bahlo, Jasmin
    Rhein, Christina
    Cramer, Paula
    Fink, Anna-Maria
    Pflug, Natali
    von Tresckow, Julia
    Stilgenbauer, Stephan
    Kreuzer, Karl-Anton
    Eckart, Michael J.
    Vehling-Kaiser, Ursula
    Schlag, Rudolf
    Balser, Christina
    Mueller, Lothar
    Wendtner, Clemens-Martin
    Fischer, Kirsten
    Eichhorst, Barbara
    Hallek, Michael
    BLOOD, 2015, 126 (23)
  • [40] Design of the dose-range finding (DRF), randomized, doubleblind, placebo-controlled study, evaluating the safety and efficacy of pridopidine for symptomatic treatment in patients with Huntington's disease
    Landwehrmeyer, G. B.
    Reilmann, R.
    Kieburtz, K.
    Eyal, E.
    Wickenberg, A.
    Bassan, M.
    MOVEMENT DISORDERS, 2014, 29 : S211 - S211
12345